Trial Profile

A Phase Ib Exploratory Trial of SP 333 in Patients with Ulcerative Colitis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolcanatide (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; Proof of concept
Sponsors Synergy Pharmaceuticals Inc

Most Recent Events

25 Feb 2016 Planned number of patients changed from 24 to 28, as reported by Synergy Pharmaceuticals media release.
11 Jan 2016 According to a Synergy Pharmaceuticals media release, the company announced positive data from this trial (n=28) for the treatment of mild-to-moderate ulcerative colitis.
11 May 2015 Recruitment is continuing, according to a Synergy Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com